drugset / Trial / NCT00972335
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Phase 2
Terminated
18 enrolled
SCRI Development Innovations, LLC
Genentech, Inc. · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma following maximal treatment with surgical resection and local radiation therapy. Although these patients are relatively rare, there is currently no established standard of treatment for a disease that causes a great deal of morbidity, and that is eventually fatal.
Timeline
- Start
- 2010-01
- Primary completion
- 2014-07
- Completion
- 2014-07
Outcome
Outcome not reported
Stopped (Enrollment): “Study terminated early due to slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Everolimus | Small molecule | 10 mg | Oral |